Safety of gefitinib in non-small cell lung cancer treatment
EHC Hsiue, JH Lee, CC Lin… - Expert opinion on drug …, 2016 - Taylor & Francis
Introduction: The development of EGFR TKI and the subsequent identification of activating
EGFR mutations have dramatically changed how NSCLC is treated. With its recent approval …
EGFR mutations have dramatically changed how NSCLC is treated. With its recent approval …
Economic Evaluation of Companion Diagnostic Testing for EGFR Mutations and First-Line Targeted Therapy in Advanced Non-Small Cell Lung Cancer Patients in …
EA Lim, H Lee, E Bae, J Lim, YK Shin, SE Choi - PLoS One, 2016 - journals.plos.org
Background As targeted therapy becomes increasingly important, diagnostic techniques for
identifying targeted biomarkers have also become an emerging issue. The study aims to …
identifying targeted biomarkers have also become an emerging issue. The study aims to …
Critical appraisal of the role of gefitinib in the management of locally advanced or metastatic non-small cell lung cancer
Y Yuan, XF Li, JQ Chen, CX Dong… - OncoTargets and …, 2014 - Taylor & Francis
Past studies have demonstrated that epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors can significantly improve clinical outcomes in patients with locally …
kinase inhibitors can significantly improve clinical outcomes in patients with locally …
Gefitinib provides similar effectiveness and improved safety than erlotinib for advanced non-small cell lung cancer: A meta-analysis
W Zhang, Y Wei, D Yu, J Xu, J Peng - Medicine, 2018 - journals.lww.com
Background: The epidermal growth factor receptor tyrosine kinase inhibitors gefitinib and
erlotinib are effective for advanced non-small cell lung cancer (NSCLC). This meta-analysis …
erlotinib are effective for advanced non-small cell lung cancer (NSCLC). This meta-analysis …
Biological characteristics and epidermal growth factor receptor tyrosine kinase inhibitors efficacy of EGFR mutation and its subtypes in lung adenocarcinoma
R Lu, CP Hu, H Yang, Y Li, Q Gu, L Wu - Pathology & Oncology Research, 2014 - Springer
Mutation of epidermal growth factor receptor (EGFR) gene has been reported to be present
in lung adenocarcinoma (LAC). In this study, we extensively investigated the impact of …
in lung adenocarcinoma (LAC). In this study, we extensively investigated the impact of …
[HTML][HTML] Second-line treatment of nsclc—the pan-erbb inhibitor afatinib in times of shifting paradigms
J Köhler - Frontiers in medicine, 2017 - frontiersin.org
In contrast to the established role of epidermal growth factor receptor (EGFR) inhibitors for
the first-line treatment of patients with non-small cell lung cancer (NSCLC) harboring …
the first-line treatment of patients with non-small cell lung cancer (NSCLC) harboring …
Bayesian Cholesky factor models in random effects covariance matrix for generalized linear mixed models
Random effects in generalized linear mixed models (GLMM) are used to explain the serial
correlation of the longitudinal categorical data. Because the covariance matrix is high …
correlation of the longitudinal categorical data. Because the covariance matrix is high …
Optimizing the treatment for advanced non–small-cell lung cancer with mutated epidermal growth factor receptor in low-income countries: a review
Introduction Osimertinib is the treatment of choice for epidermal growth factor receptor
(EGFR)-mutated advanced non–small-cell lung cancer (NSCLC). Because of its high price …
(EGFR)-mutated advanced non–small-cell lung cancer (NSCLC). Because of its high price …
Effects of removing reimbursement restrictions on targeted therapy accessibility for non-small cell lung cancer treatment in Taiwan: an interrupted time series study
JC Hsu, CF Wei, SC Yang - BMJ open, 2019 - bmjopen.bmj.com
Interventions Targeted therapies have been proven to provide clinical benefits to patients
with metastatic non-small cell lung cancer (NSCLC). Gefitinib was initially approved and …
with metastatic non-small cell lung cancer (NSCLC). Gefitinib was initially approved and …
[HTML][HTML] A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth …
SX Soh, FJ Siddiqui, JC Allen, GW Kim, JC Lee… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Background A germline deletion in the BIM (BCL2L11) gene has been shown to impair the
apoptotic response to tyrosine kinase inhibitors (TKIs) in vitro but its association with poor …
apoptotic response to tyrosine kinase inhibitors (TKIs) in vitro but its association with poor …